

# SIMRIS GROUP

## INTERIM REPORT

### JANUARY–MARCH 2026

#### QUARTER 1, JANUARY – MARCH 2026

- Net revenue increased by 167% to SEK 424k (159k).
- EBITDA improved by 41% to SEK -2 183k (-3 724k).
- EBIT/Operating result improved by 23% to SEK -5 626k (-7 288k).

#### KEY EVENTS DURING THE QUARTER

- Simris Group enters into Memorandum of Understanding regarding divestment of assets in Hammenhög.
- Extraordinary General Meeting 19 January 2026 resolved to elect Julian Read as new board member, adopt new articles of association with increased share capital limits and share limits, and approve (i) a directed issue of units to investors at SEK 0.05 per unit, each unit consisting of one share and two warrant, corresponding to 140 905 267 units (ii) a directed issue of class B shares to management at SEK 0.05 per share, corresponding to 36 783 108 number shares.
- Simris evaluating options to expand its ADC-payload development programme and prepare for the next funding round to accelerate its plans.

#### KEY EVENTS AFTER THE END OF THE QUARTER

- Simris Group advances divestment process for assets in Hammenhög by entering into a Memorandum of Understanding with a second prospective buyer, while the first prospective buyer remains engaged.

#### THE PERIOD IN BRIEF - GROUP

SEK thousands	Jan-Mar 2026	Jan-Mar 2025	Δ	Full year 2025
Net revenue	424	159	167%	1 615
EBITDA	-2 183	-3 724	41%	-15 539
EBIT / Operating result	-5 626	-7 288	23%	-29 562
Result before tax	-6 973	-6 795	-3%	-30 003
Cash flow from operating activities	-3 967	-5 284	25%	-16 045
Cash at the end of the period	10 759	2 998	259%	1 465

## CEO UPDATE

Since the last quarterly update, good progress has been made across our research and development programmes. Our commitment to advancing the next generation of antibody-drug conjugate (ADC) payloads remains unwavering, and the work underway demonstrates the breadth of innovation our team is delivering.

We have now initiated studies on a number of new payload approaches, each designed to overcome key limitations in current ADC therapeutics and to unlock new clinical possibilities.

### Multi-Target Microcystin-ADC Studies

We have initiated preclinical studies to evaluate its proprietary Microcystin-based ADC payload platform across selected solid tumour and haematologic cancer models. The studies use antibodies against established oncology targets and compare multiple Microcystin payload variants to assess their preclinical potency, selectivity and tolerability profiles. The results are expected to support data-driven lead-candidate selection and guide further development of the Microcystin-ADC platform.

### Advanced Payload Innovation

We have recently initiated an additional study that builds on the intellectual property of our ADC payload platform, exploring a novel approach to payload design within this framework. This study is aligned with our broader effort to advance payload technologies and refine their performance in ADCs and to achieve selective activity and improved tolerability.

Our mission at Simris is to pioneer the next generation of ADC payloads that are more specific, more effective, and safer than those currently available. The diverse payload technologies we are developing reflect our conviction that innovation in payload design is the key to unlocking the full potential of ADC therapeutics.

### Strategic Options Evaluation

As we progress our pre-clinical programmes, the Board continues its evaluation of two strategic pathways for the Company, both of which would require additional funding and could fundamentally shape Simris' trajectory.

The first option focuses on continued investment in our Microcystin-ADC platform, including the expansion of MC-payload variants through advanced molecular engineering. This approach builds directly on our core scientific strength - the discovery and optimization of novel payload based on cyanobacteria-derived natural product scaffolds and refined through targeted semi-synthetic modification.

The second option represents a unique opportunity to integrate a highly experienced ADC development team with clinically validated novel payload expertise. This would enable Simris to initiate a second, parallel ADC programme whilst significantly strengthening our internal capabilities across ADC design, development and clinical translation. Whilst this option would be more capital intensive, it holds the potential to position Simris for a first in-human clinical study as early as 2028, thereby accelerating our time to a meaningful commercial inflection point. Critically, this pathway would evolve Simris from a payload innovation company into an integrated ADC development platform, combining our differentiated payload discovery capabilities with in-house expertise in ADC design and pre-clinical development.

Since the initial evaluation of these options, management and the Board have made substantial progress in gathering detailed technical, financial and strategic information. We are currently in detailed discussions with experienced ADC development teams and are narrowing our options through careful evaluation of



partnership opportunities. We anticipate reaching a decision on the strategic direction during the second quarter, at which point we will provide the market with a clear vision of how we intend to accelerate value creation for our shareholders.

### **Hammenhög Asset Sale Progress**

Regarding the sale of our Hammenhög facility, we recently announced that we are advancing our divestment process with two prospective buyers. Following our announcement in January of this year that the company had entered into a Memorandum of Understanding (MoU) with a prospective buyer, Simris entered into a MoU on 12 May 2026 with a second prospective strategic buyer based in Asia. Under this new MoU, the prospective acquirer has been granted a 45-day exclusivity period to conduct comprehensive due diligence and submit a firm and binding offer by 26 June 2026.

In addition, the first strategic prospective buyer, has reaffirmed its interest in acquiring the Company's microalgae production assets and is actively pursuing capital to fund the transaction.

The parties agreed on an indicative valuation principle whereby the purchase price is expected to be in line with the book value of the assets, subject to satisfactory completion of legal, technical and operational due diligence.

The Board of Directors of Simris considers the potential transactions to be aligned with the Company's strategic priorities and believes that the successful completion of a divestment will strengthen the Company's financial position and allow it to focus resources on its core strategic objectives.

Simris will provide further updates as the divestment process progresses and as developments warrant.

I am tremendously proud of the creativity, dedication, and scientific rigour our team continues to bring to this work. We remain committed to advancing these programmes with the urgency and quality they deserve, with the ultimate goal of delivering new treatment options that will improve outcomes for cancer patients worldwide.

Thank you for your continued confidence and support.

**Daniel Kubitza**

Interim CEO Simris Group

## OVERVIEW

### NET REVENUE AND PROFIT

The sales for the quarter increased by 167% and amounted to SEK 424k (159k).

The EBITDA result for the quarter improved by 41% to SEK -2 183k (-3 724k). The EBIT/ Operating result for the quarter improved by 23% to SEK -5 626k (-7 288k).

The financial net for the quarter amounted to SEK -1,347k (-493k). As of 1 January 2026, exchange rate differences attributable to the EUR-denominated earn-out liability related to the acquisition of Simris Biologics are recognized in the Group's financial income and expenses. In the Parent Company, such exchange rate adjustments continue to be capitalized as part of the acquisition value of the shares. For the quarter, exchange rate adjustments related to the earn-out liability concerning Simris Biologics amounted to SEK -996k (0k).

The total inventory value amounted to SEK 1 089k (1 077k) at the end of the interim period. All inventory accounted for at the end of the interim period is related to Simris Biologics.

### FIXED ASSETS

The total book value of the Group's fixed assets amounted to SEK 129 972k (142 632k) at the end of the quarter. Intangible Assets at the quarter were SEK 119 334k (128 670k). Tangible Assets at the end of the year were SEK 10 638k (13 962k).

The depreciation of fixed assets was made according to relevant accounting standards with SEK 3 443k (3 564k) during the quarter. Fixed assets are depreciated over 5–10 years for most fixtures and fittings, and over the remaining lifetime for patents (15 years for the patents and technology gained through the Cyano Biotech acquisition, now renamed to Simris Biologics), and up to 50 years for the buildings.

### LIQUIDITY AND FINANCING

Cash flow from operating activities improved by 25 percent to SEK -3 967k (-5 284k) during the quarter. Cash flow amounted to SEK 9 294k (-1 052k) for the quarter. At the end of the quarter, cash and cash equivalents amounted to SEK 10 759k (2 998k). The total liabilities at the end of the period amounted to SEK 136 975k (147 721k).

The deferred tax liability at the end of the quarter amounting to SEK 35 800k (38 677k) is not a payable debt as it is related to the purchase price allocation of Simris Biologics.

It is important to note that €8m of the long-term debt on the balance sheet is associated with the acquisition of Cyano Biotech (now Simris Biologics). This is the maximum earn-out remaining to be paid for the acquisition of the ADC platform. For this to become payable, Simris Biologics would have to first earn sales revenue of at least €80m from the ADC platform over the next 15 years. This revenue would be expected to be at a very high profit margin. Importantly, Simris Group has executed a back-to-back agreement with Simris Biologics whereby Simris Biologics will recompense Simris Group for the amount of this future earn-out payment.

On December 23, 2024, Simris entered into convertible loan agreements totaling EUR 600k, with an option for the lender to increase the amount by an additional EUR 900k. In addition, at the extraordinary general meeting held on January 20, 2025, the Company resolved to enter into convertible loan agreements totaling EUR 140k with related parties and members of management. The loans were provided by Frank Puccio (EUR 50k), Royce CoLabs AB, a company controlled by Jonathan Royce (EUR 10k), Magnus Högström (EUR 30k), Arminnovate Ltd, a company controlled by Dr. Alexis Roberts-McIntosh (EUR 20k), and Christoffer Tell AB, a company controlled by Christoffer Tell (EUR 30k). The loans initially carried interest at 1.0 percent per month and matured on December 31, 2025. At the annual general meeting held on May 28, 2025, the maturity date was extended to March 31, 2026. From August 1,

2025, no further interest accrued on the loans. The lenders had the right to convert outstanding loan amounts, including accrued interest, into newly issued class B shares at a subscription price of SEK 0.05 per share, subject to adjustment in future capital raisings. Following the resolutions at the extraordinary general meeting held on January 19, 2026, outstanding loan amounts and accrued interest under the EUR 600k facility were set off through a directed issue of 140 905 267 units, each consisting of one (1) class B share and two (2) warrants, corresponding to 140 905 267 new class B shares and 281 810 534 warrants. The share capital increased by SEK 1 409 052.67 as a result of the issuance of the class B shares and may increase by an additional SEK 2 818 105.34 upon full exercise of the warrants. At the same extraordinary general meeting, outstanding loan amounts and accrued interest relating to the EUR 140k management and related-party loans were converted into newly issued class B shares at a subscription price of SEK 0.05 per share. The conversion was allocated as follows: Frank Puccio 11 654 346 shares, Royce CoLabs AB 2 330 123 shares, Magnus Högström 7 006 032 shares, and Christoffer Tell AB 6 992 607 shares. In addition, CEO Daniel Kubitzka invested EUR 40k in cash and received 8 800 000 newly issued class B shares.

The Brand Laboratories FZ (TBL) had previously provided the business with a loan facility of €778k. The facility maturity date is 1 January 2027, and interest was charged at 1.0% per month until 31 July 2025. The total loan including accumulated interest is per 31 July 2025 €856k. After August 1, 2025 Interest will be charged at 0% per month.

On 16 December 2025, the Board of Directors, by virtue of the authorization granted by the annual general meeting held on 28 May 2025, resolved on a directed issue of 330 000 000 units, each unit consisting of one (1) class B share and two (2) warrants of series 2025/2027, at a subscription price of SEK 0.05 per unit. The warrants were issued free of charge. Through the issue, the Company received proceeds of approximately EUR 1,5 million before transaction costs. The issue resulted in the issuance of 330 000 000 new class B shares, increasing the share capital by SEK 3 300 000, from SEK 6 251 448,98 to SEK 9 551 448,98. Each warrant entitles the holder to subscribe for one (1) new class B share at SEK 0.05 during the period up to and including 31 December 2027. Upon full exercise of all warrants, an additional 660,000,000 class B shares may be issued, corresponding to a further increase in share capital of SEK 6,600,000. The transaction was subscribed to in December 2025 and January 2026. The transaction is fully paid for and registered in January 2026.

The Board of Directors wishes to inform stakeholders that the company's current cash reserves may not be sufficient to cover ongoing operations through the end of the calendar year. We recognize the gravity of this situation and are actively working on multiple fronts to secure the necessary funding to support the company's ongoing operations and future growth. Efforts are underway and the board explores various financing options, including debt refinancing, potential loans, new investment opportunities, and strategic partnerships. The Board remains committed to ensuring the long-term stability and success of the company and will continue to update stakeholders as progress is made.

## EQUITY

The Group's equity amounted to SEK 5 486k (- 1 071k) at the end of the quarter. The solidity was 3,9 percent, compared with -0,3 percent on December 31, 2025.

The total number of shares amounted to 1 349 793 273 B and the share capital amounted to SEK 13 497 932,73. Each share has a quota value amounting to 0.01 SEK.

## OPTION PROGRAM

At the end of the quarter Simris Group had two outstanding option programs to capital raise of units.

Series 2025/2027 consists of 660 000 000 options and was issued to the investors in January 2026. The options have a term of three years, and each option gives the right to subscription of one B shares at a subscription price of SEK 0,05 per share until end of 2027. Utilization of outstanding options corresponds to a dilution of the share capital by 32,8 percent.

Series 2026/2027 consists of 281 810 534 options and was issued to the investors in January 2026. The options have a term of three years, and each option gives the right to subscription of one B shares at a subscription price of SEK 0,05 per share until end of 2027. Utilization of outstanding options corresponds to a dilution of the share capital by 17,3 percent.

## STAFF AND ORGANIZATION

The average number of full-time equivalents (FTEs) employed during the quarter amounted to 5 (6). At the end of the quarter, the Group had 5 FTEs excluding the CEO and the CFO that are contracted as consultants.

## PARENT COMPANY

Simris Group AB is the parent company. Net revenue for the Parent Company during the quarter amounted to SEK 0 (0). EBIT/ Operating result amounted to SEK -2 099k (-2 297k) for the quarter. Result before tax amounted to SEK -4 407k (-2 102k) for the quarter. During the quarter, shares in subsidiary Simris Biologics were written down by SEK 1 966k equal to the shareholder contribution that was transferred to Simris Biologics during the quarter.

## TRANSACTIONS WITH RELATED PARTIES

At the extraordinary general meeting held on January 20, 2025, Simris Group AB (publ) resolved to enter into loan agreements totaling EUR 140 000 with related parties, including Frank Puccio (EUR 50 000), Royce CoLabs AB, a company controlled by Jonathan Royce (EUR 10 000), Magnus Högström (EUR 30 000), Arminnovate Ltd, a company controlled by Dr Alexis Roberts-McIntosh (EUR 20 000), and Christoffer Tell AB, a company controlled by Christoffer Tell (EUR 30 000). Due to conflicts of interest among board members, the agreements were submitted to the general meeting for approval in accordance with the Swedish Companies Act. The loans carry an interest rate of 1.0 percent per month and mature on December 31, 2025. The lenders have the right to convert the outstanding loan amounts, including accrued interest, into B-shares at a subscription price of SEK 0.05 per share, subject to adjustment in the event of a future capital raise. At the annual general meeting held on May 28, 2025, Simris Group AB (publ) resolved to extend the maturity date to March 31, 2026. From 1 August 2025 the interest rate of the loan is 0.0 percent per month. At the extraordinary general meeting held on 19 January 2026, it was resolved that the outstanding loan amounts be set off against newly issued class B shares at a subscription price of SEK 0,05 per share, Frank Puccio 11 654 346 shares, Royce CoLabs AB 2 330 123 shares, Magnus Högström 7 006 032 shares and Christoffer Tell AB 6 992 607 shares.

In addition to normal Board work during the quarter, Board Directors performed consulting services for the company, of which Magnus Högström SEK 28k and Jonathan Royce SEK 30k.

## ACCOUNTING PRINCIPLES

Simris Group prepares its accounts in accordance with the Annual Accounts Act and the Accounting Boards general advice 2012:1(K3). Information on accounting principles in general is provided in the Annual Report for 2025.

## AUDIT

This report has not been reviewed by Simris Group's auditor.

## RISKS AND UNCERTAINTIES

Simris Group's operations, financial position and earnings can be affected by a number of risks and uncertainties. These are described in Simris Group's Annual Report for 2025, at [www.simrisgroup.com](http://www.simrisgroup.com).

Simris Group is in the start-up phase and still lacks sufficient earnings to cover the costs of the business through sales revenue. Simris Group is reliant upon planned additional external funding to be able to continue its operations, repay loans, and implement growth plans. Whilst the Board is confident that the business is in its strongest position ever, and that it will be able to raise the funds required for future



investment and growth, there is always a risk that capital markets change and that new capital cannot be accessed when needed, or that new capital cannot be obtained on satisfactory terms, or that the procured capital is insufficient to finance the planned operations in accordance forecasts and objectives.

**13 May 2026**

The Board of Directors and the CEO confirm that this report provides a fair overview of the Group's operations, position and results.

**Daniel Kubitza**  
Interim CEO

**Jonathan Royce**  
Chairman

**Magnus Högström**  
Board Director

**Frank Puccio**  
Board Director

**Richard Todd**  
Board Director

**Hadrien Forterre**  
Board Director

**Julian Read**  
Board Director

## INCOME STATEMENT - CONSOLIDATED GROUP

SEK thousands	Jan-Mar 2026	Jan-Mar 2025	Full year 2025
Net revenue	424	159	1 615
Change of finished goods and work in progress	0	0	610
Other operating income	766	0	1 780
Raw materials and consumables	-201	-80	-460
Other external expenses	-1 702	-2 470	-13 259
Personnel expenses	-1 470	-1 333	-5 825
Depreciation and amortization	-3 443	-3 564	-14 023
<b>Operating result / EBIT</b>	<b>-5 626</b>	<b>-7 288</b>	<b>-29 562</b>
Financial net	-1 347	493	-441
<b>Result before tax</b>	<b>-6 973</b>	<b>-6 795</b>	<b>-30 003</b>
Tax	787	801	3 192
<b>Result for the period</b>	<b>-6 186</b>	<b>-5 994</b>	<b>-26 811</b>
(Attributable to the parent company's shareholders)	<b>-6 186</b>	<b>-5 994</b>	<b>-26 811</b>

## BALANCE SHEET - CONSOLIDATED GROUP

SEK thousands	31 Mar 2026	31 Mar 2025	31 Dec 2025
<b>Assets</b>			
<b>Fixed Assets</b>			
Intangible assets	119 334	128 670	120 553
Tangible assets	10 638	13 962	11 355
<b>Total Fixed Assets</b>	<b>129 972</b>	<b>142 632</b>	<b>131 908</b>
<b>Current Assets</b>			
Inventory	1 089	481	1 077
Other receivables	641	539	13 931
Cash and bank balances	10 759	2 998	1 465
<b>Total Current Assets</b>	<b>12 489</b>	<b>4 018</b>	<b>16 473</b>
<b>Total Assets</b>	<b>142 461</b>	<b>146 650</b>	<b>148 381</b>
<b>Equity and Liabilities</b>			
Equity	5 486	-1 071	-470
<b>Provisions</b>			
Deferred tax	35 800	38 677	36 170
<b>Liabilities</b>			
Long-term Liabilities	88 568	88 471	87 680
Short-term Liabilities	12 607	20 573	25 001
<b>Total Liabilities</b>	<b>136 975</b>	<b>147 721</b>	<b>148 851</b>
<b>Total Equity and Liabilities</b>	<b>142 461</b>	<b>146 650</b>	<b>148 381</b>

## CASH FLOW ANALYSIS - CONSOLIDATED GROUP

SEK thousands	Jan-Mar 2026	Jan-Mar 2025	Full year 2025
Cash flow from operating activities before changes in working capital	-2 523	-3 575	-15 933
Cash flow from working capital	-1 444	-1 709	-112
<b>Cash flow from operating activities</b>	<b>-3 967</b>	<b>-5 284</b>	<b>-16 045</b>
Cash flow from investing activities	-182	0	-224
Cash flow from financing activities	13 443	6 336	15 788
<b>Cash flow for the period</b>	<b>9 294</b>	<b>1 052</b>	<b>-481</b>
Cash and cash equivalents opening balance	1 465	1 946	1 946
<b>Cash and cash equivalents closing balance</b>	<b>10 759</b>	<b>2 998</b>	<b>1 465</b>

## CHANGES IN EQUITY - CONSOLIDATED GROUP

SEK thousands	Jan-Mar 2026	Jan-Mar 2025	Full year 2025
Opening balance	-470	5 641	5 641
Issue	11 909	0	21 069
Issue costs	-803	0	0
Translation differences	1 036	-718	-369
Result for the period	-6 186	-5 994	-26 811
<b>Closing balance</b>	<b>5 486</b>	<b>-1 071</b>	<b>-470</b>

## KEY FIGURES - CONSOLIDATED GROUP

	Jan-Mar 2026	Jan-Mar 2025	Full year 2025
Net revenue (kSEK)	424	159	1 615
EBIT (kSEK)	-5 626	-7 288	-29 562
Cash at the end of the period (kSEK)	10 759	2 998	1 465
Equity (kSEK)	5 486	-1 071	-470
Earnings per share (SEK)	neg.	neg.	neg.
Earnings per share after full dilution (SEK)	neg.	neg.	neg.
Equity per share (SEK)	0,004	-0,002	-0,001
Equity per share after full dilution(SEK)	0,002	-0,002	-0,001
Number of shares, average	1 155 122 133	417 712 430	574 194 370
Number of shares, end of period	1 349 793 273	504 764 755	842 104 898
Number of shares after full dilution*	2 291 603 807	504 764 755	842 104 898
Solidity (%)	3,9	-0,7	-0,3
Balance sheet total (kSEK)	142 461	146 650	148 381
Cash liquidity (%)	90	17	62
Average number of employees	5	6	6

\*Simris Group has two outstanding warrant programs.

## INCOME STATEMENT - PARENT COMPANY

SEK thousands	Jan-Mar 2026	Jan-Mar 2025	Full year 2025
Net revenue	0	0	0
Other operating income	0	0	28
Other external expenses	-1 195	-1 451	-8 285
Personnel expenses	-157	-100	-496
Depreciation and amortization	-747	-746	-2 986
<b>Operating result / EBIT</b>	<b>-2 099</b>	<b>-2 297</b>	<b>-11 739</b>
Financial net	-2 308	195	-3 558
<b>Result before tax</b>	<b>-4 407</b>	<b>-2 102</b>	<b>-15 297</b>
Tax	0	0	0
<b>Result for the period</b>	<b>-4 407</b>	<b>-2 102</b>	<b>-15 297</b>

## BALANCE SHEET - PARENT COMPANY

SEK thousands	31 Mar 2026	31 Mar 2025	31 Dec 2025
<b>Assets</b>			
<b>Fixed Assets</b>			
Tangible assets	9 215	12 200	9 962
Financial assets	131 792	129 046	130 795
<b>Total Fixed Assets</b>	<b>141 007</b>	<b>141 246</b>	<b>140 757</b>
<b>Current Assets</b>			
Other receivables	274	367	13 528
Cash and bank balances	9 751	2 461	1 097
<b>Total Current Assets</b>	<b>10 025</b>	<b>2 828</b>	<b>14 625</b>
<b>Total Assets</b>	<b>151 032</b>	<b>144 074</b>	<b>155 382</b>
<b>Equity and Liabilities</b>			
<b>Equity</b>	50 672	36 099	43 972
<b>Liabilities</b>			
Long-term Liabilities	88 568	88 471	87 680
Short-term Liabilities	11 792	19 504	23 730
<b>Total Liabilities</b>	<b>100 360</b>	<b>107 975</b>	<b>111 410</b>
<b>Total Equity and Liabilities</b>	<b>151 032</b>	<b>144 074</b>	<b>155 382</b>

## ABOUT SIMRIS GROUP

Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics. Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

## FINANCIAL CALENDAR:

Annual General Meeting	24 June 2026
Interim Report Q2, 2026	12 August 2026
Interim Report Q3, 2026	11 November 2026
Year-end Report 2026	24 February 2027

## Certified Adviser

Amudova AB is the Company's Certified Adviser on Nasdaq First North and can be reached at [info@amudova.se](mailto:info@amudova.se) or +46 (0) 8-546 017 58.

## FOR MORE INFORMATION:

Daniel Kubitzka, interim CEO  
 Phone: +33 6 71 04 21 52  
 Email: [IR@simris.com](mailto:IR@simris.com)

## KEY FIGURE DEFINITIONS

**Balance sheet total** - The sum of all assets in the balance sheet or sum of all liabilities and equity.

**Equity per share** - Adjusted equity (equity and untaxed reserves less deferred tax) divided by the number of shares at the end of the period.

**Equity per share after full dilution** - Adjusted equity (equity and untaxed reserves less deferred tax) divided by the number shares at the end of the period taking into account after conversion and adjusted for effect of share-based payments.

**Cash liquidity** - Current assets excluding inventories and work in progress as a percentage of current liabilities

**Net revenue** - Operating main income, invoiced costs, side income and income corrections.

**Earnings per share** - Earnings for the period divided by the number of shares after the end of the period.

**Earnings per share after full dilution** - Earnings for the period divided by number shares after the end of the period, taking into account after conversion and adjusted for effect of share-based payments.

**EBIT/ Operating result** - Result before financial expenses and tax.

**Solidity** - Adjusted equity at the end of the period as a percentage of total asset.

*This information is information that Simris Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CEST on 13 May 2026.*